Biotechnica: Getting smaller and more international


Hanover - From October 5-7 the Biotechnica in Hanover attracted 9.500 visitors and 500 enterprises. This is the smallest edition for years. "In view of framework conditions currently affecting the biotech industry, this is a solid outcome indeed," reported Stephan Kühne. Indeed in 2008 and 2009 some 11.000 visitors turned up and the number of exhibitors in 2010 declined at a rate of 20% respectively compared with 2009. Whether there will be a Biotechnica 2012 is not yet decided. Before 2008, Biotechnica was staged every two years, starting in 1985. Some companies still cling to the old rhythm and therefore only show up in uneven years, making the even years like 2010 weaker editions. Kühne didn't say if the Deutsche Messe AG will uphold the yearly editions. "We proceed step by step", he said on the final press conference on Thursday, October 7th. Kühne wants to sharpen the profile of the event. One tool for this purpose is the conference program, which will be extended in 2011. 2010 the show's conferences, forums and workshops drew attendance by over 3,000. This year's range of topics extended from biomedicine and
bioinformatics to the food markets of the future. Even if it's getting smaller, Biotechnica is getting more international. Around 25 percent of visitors came from abroad - five percent more than the previous year. Attendance was up from Europe, above all from the United Kingdom, the Netherlands and France, but also from the United States and Russia. The biggest visitor nations consisted of the United Kingdom, the Netherlands, France, Switzerland and the United States
Carrying a prize purse of EUR 75,000, the EUROPEAN BIOTECHNICA AWARD was presented at the opening event on October 4th. The winner was the Galapagos NV company, based in Mechelen, Belgium. The company specializes in research and development of anti-body and small molecular therapies for the treatment of various diseases such as cancer, diabetes or Alzheimer's. A further 45,000 euros in non-cash prizes went to Galapagos and the other Finalists, Apeiron of Austria and Addex Pharmaceuticals of Switzerland. The non-cash prizes comprise free strategy and investment consultancy services provided by Capgemini Consulting and a media service packages facilitated by the European Biotechnology News.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • NEWRON (CH)22.65 CHF9.69%
  • VERNALIS (UK)45.00 GBP4.65%
  • KARO BIO (S)40.00 SEK4.44%


  • PROTHENA PLC (IE)50.02 USD-7.70%
  • BIONOR PHARMA (N)0.44 NOK-6.38%


  • DIAMYD MEDICAL -B- (S)7.25 SEK68.6%
  • KARO BIO (S)40.00 SEK34.2%
  • NEWRON (CH)22.65 CHF33.6%


  • BIONOR PHARMA (N)0.44 NOK-27.9%
  • NOVOZYMES (DK)284.40 DKK-14.0%
  • RENEURON (UK)2.75 GBP-12.7%


  • KARO BIO (S)40.00 SEK2497.4%
  • NICOX (F)10.26 EUR451.6%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%


  • BB BIOTECH (D)46.74 EUR-81.7%
  • EVOCUTIS (UK)0.04 GBP-78.9%

No liability assumed, Date: 24.08.2016


All Events